Olema Pharmaceuticals
OLMA
133 hedge funds and large institutions have $248M invested in Olema Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 43 reducing their positions, and 47 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less funds holding
Funds holding: 156 → 133 (-23)
27.95% less ownership
Funds ownership: 124.4% → 96.44% (-28%)
40% less capital invested
Capital invested by funds: $415M → $248M (-$167M)
49% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 47
79% less call options, than puts
Call options by funds: $27K | Put options by funds: $128K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$13.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.97M |
| 3 |
PC
Pier Capital
Stamford,
Connecticut
|
+$2.74M |
| 4 |
Goldman Sachs
New York
|
+$1.8M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.2M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$9.63M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.99M |
| 5 |
BCM
Boxer Capital Management
San Diego,
California
|
-$3.79M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
US Bancorp
Minneapolis,
Minnesota
| – | -$1.61K | -277 | Closed |
|
|
S
177
SignatureFD
Atlanta,
Georgia
| – | -$944 | -162 | Closed |
|
178
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$875 | -150 | Closed |
|
179
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$501 | -86 | Closed |
|
|
AAP
180
Arax Advisory Partners
Denver,
Colorado
| – | -$379 | -65 | Closed |
|
|
C
181
Covestor
London,
United Kingdom
| – | +$50 | +10 | +143% |
|
OLMA Hedge Fund Activity: Q1 2025 in Review
133 of the 7,460 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q1 2025, worth a combined $248M — down 40% from $415M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of OLMA and 24 opened new positions — a net loss of 23 holders — while 43 trimmed existing stakes and 48 added.
The largest buyer was Franklin Resources, adding an estimated $13.8M. The largest seller was Point72 Asset Management, cutting an estimated $11.2M.
- 133 institutional investors held Olema Pharmaceuticals (OLMA) as of Q1 2025, down from 156 in Q4 2024.
- Funds reported $248M of Olema Pharmaceuticals stock for Q1 2025, down 40% quarter-over-quarter.
- 24 funds opened new Olema Pharmaceuticals positions in Q1 2025 and 47 closed out, a net change of -23 holders.
- The largest Olema Pharmaceuticals buyer in Q1 2025 was Franklin Resources, an estimated $13.8M added.
- The largest Olema Pharmaceuticals seller in Q1 2025 was Point72 Asset Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q1 2025.